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Abstract
Adeno-associated viral (AAV) vectors 2 and 8 have been used in clinical trials for patients with hemophilia, and
data suggest that the capsid-specific CD8 + T cell response has had a negative impact on therapeutic success. To
date the pattern of capsid cross-presentation from AAV2 and AAV8 transduction in vivo has not been elucidated.
Previously, we have demonstrated that an engineered AAV2 virus carrying the immune-dominant SIINFEKL
peptide in the capsid backbone was indistinguishable from wild type with respect to titer, tropism, and the
ability to induce capsid-specific CD8 + T cell responses in vivo. In this study, we used the same strategy to
engineer an AAV8 vector and demonstrated that antigen from SIINFEKL peptide-integrated AAV8 capsid was
effectively presented via either plasmid transfection or AAV8 transduction in vitro. The tissue tropism and
transgene expression kinetics of the engineered AAV8 vector in vivo were identical to that of wild-type AAV8.
Animal studies show that capsid antigen presentation from AAV transduction was dose dependent, and more
importantly, the proliferation of capsid-specific CD8 + T cells had similar kinetics (detectable before 30 days and
undetectable after 40 days) for both AAV2 and AAV8 vectors. Elucidation of the kinetics of capsid antigen
presentation from AAV transduction by various serotypes provides new insight into the potential impact CD8 +
T cells can have during clinical trials and may help with rational design of effective strategies to prevent capsid-
specific CD8 + T cell-mediated elimination of AAV-transduced target cells.
Introduction
Adeno-associated virus (AAV) is a single-strandedDNA virus with a genome composed of the rep and cap
genes flanked by inverted terminal repeats (ITRs). One AAV
virion contains three capsid proteins—VP1, VP2, and VP3—at
a ratio of 1:1:8. Substitution of the rep and cap genes with a
therapeutic gene generates an AAV vector. AAV serotype 2
(AAV2) was first isolated from adenovirus contamination and
has been extensively studied for its virology and as a gene
delivery vehicle. Eleven other AAV serotypes and more than
100 AAV variants have been isolated and studied to extend
AAV vector tropism with enhanced transduction efficiency
for the purpose of gene therapy. AAV vectors have been used
in more than 80 clinical trials, with no serious AAV-related
toxicities. Promising results have been achieved in two clinical
trials in patients with Leber disease or hemophilia (Manno
et al., 2006; Maguire et al., 2008, 2009; Simonelli et al., 2010;
Nathwani et al., 2011): For Leber disease, after delivery of an
AAV2 vector encoding RPE65 into the retina, patients’ vision
was restored (Maguire et al., 2008, 2009; Simonelli et al., 2010).
For patients with hemophilia B, an AAV2 vector encoding
human coagulation factor 9 (F9) was delivered via an artery,
resulting in 10% blood level detection of F9; unfortunately,
therapeutic levels of F9 lasted only 4 weeks, and then returned
to the baseline level, concurrent with elevation of liver
transaminases. No CD8 + cytotoxic T lymphocyte (CTL) re-
sponse to F9 protein was detected, but peptides from the
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AAV2 capsid induced lymphocyte activation, which sug-
gested that capsid-specific CTLs destroyed the AAV2-
transduced liver cells and resulted in the failed treatment
(Manno et al., 2006). In a second hemophilia clinical trial, an
AAV8 vector was used to deliver F9 into the liver via pe-
ripheral vein administration. A capsid-specific CTL response
was detected in all patients at various time points after AAV
delivery (Nathwani et al., 2011), and two patients receiving a
high vector dose had liver transaminase elevation coincident
with detection of an AAV8 capsid-specific T cell response. The
clinical findings that a capsid-specific T cell response is eli-
cited from AAV vector transduction was not previously ob-
served in preclinical studies (Nathwani et al., 2011). Later
studies, however, showed that indeed a capsid-specific CTL
response could be mounted from AAV vector transduction
via muscular injection or immunization with AAV vector-
pulsed dendritic cells (Chen et al., 2006; Li et al., 2007; Wang
et al., 2007). Clinical data indicate that the capsid-specific CTL
response is dose dependent, such that a stronger CTL re-
sponse results from higher AAV particle delivery (Manno
et al., 2006; Nathwani et al., 2011). The capsid CTL response
was elicited regardless of administration route (Manno et al.,
2006; Mingozzi et al., 2009; Nathwani et al., 2011), that is,
whether the vector was delivered by muscular injection
(Mingozzi et al., 2009), artery injection (Manno et al., 2006), or
peripheral vein injection (Nathwani et al., 2011).
To mimic the findings from clinical trials, AAV2 vectors
have been used to test the kinetics of antigen presentation in
animal models. Such studies have indicated that capsid-
specific T cell activation is observed at early time points after
vector application (H. Li et al., 2011). Among 12 serotypes
and more than 100 variants, AAV serotype 8 is considered to
be the most efficient for liver transduction (Gao et al., 2006;
Wu et al., 2008; C. Li et al., 2011; Wang et al., 2012). Fur-
thermore, peak levels of transgene expression are obtained
significantly sooner with AAV8 as compared with AAV2
packaged vectors (Wu et al., 2008). To determine whether the
kinetics of a capsid-specific CTL response in vivo differ be-
tween AAV2 and AAV8, we adopted a previously used
strategy of substituting the capsid HI loop with the chicken
ovalbumin (OVA)-derived SIINFEKL peptide to generate an
AAV8OVA cassette (Li et al., 2009b). Using the engineered
AAV8OVA vector, we found that AAV8 capsid antigen was
properly processed and presented on the cell surface with
MHC class I molecules to activate OVA-specific lymphocytes
either through endogenous production of capsid or by AA-
V8OVA vector transduction in vitro. In vivo administration of
AAV8OVA induced tropism and kinetics of transgene ex-
pression similar to those of wild-type AAV8 vector. Promi-
nently, similar in vivo kinetics of capsid antigen presentation
were observed for AAV8OVA and AAV2OVA vectors.
Materials and Methods
Constructs
The SIINFEKL immunodominant epitope was cloned
into the AAV8 capsid by substitution of the HI loop with
the eight-amino acid sequence as described previously for
generation of the pXR2/OVA cassette (Li et al., 2009). We
first used the PCR primers F1R1-0 and F2-0R2 (Supplemen-
tary Fig. S1; supplementary data are available online at
www.liebertonline.com/hum), which were designed to in-
troduce the SIINFEKL peptide into the HI loop of the AAV8
capsid, using the pXR8 template to match the OVA peptide
positioning with that placed in the AAV2 capsid for pXR2/
OVA based on alignment (Supplementary Fig. S1). The PCR
products from primers F1R1 and F2R2 were digested with
SalI and NotI, respectively. pXR8/OVA-0 was generated by
insertion of digested PCR products into the pXR8 backbone
with SalI and NotI digestion. However, virus production
yield from pXR8/OVA-0 transfection was low (data not
shown). We tested whether repositioning the swapped
peptide downstream by one or two amino acids would im-
prove virus yield. To this end we used primer sets F1R1-1/
F2-1R2 and F1/R1-2/F2-2R2 to generate the constructs
pXR8/OVA-1 and pXR8/OVA-2, respectively. These two
constructs produced higher virus yields, with the highest
yield coming from pXR8/OVA-1 and matching the yield
from wild-type AAV8 vector (data not shown). So,
throughout this study, pXR8/OVA-1 was used to make
AAV8OVA vectors. All pXR8/OVA constructs were verified
by sequencing. The constructs pTR-CBA-luc and pTR-CBA-
AAT are AAV2 TR-containing plasmids encoding the firefly
luciferase and human a1-antitrypsin (AAT) transgenes, re-
spectively, and were driven by the chicken b-actin promoter
(CBA).
Cells and virus
HEK293 and HepG2/H-2Kb were maintained at 37C and
5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal calf serum,
penicillin (100 U/ml), and streptomycin (100 g/ml). AAV
virus production was done as previously described, using
three-plasmid cotransfection in 293 cells (Xiao et al., 1998).
The viral titer was determined by Southern dot blot.
Mice
C57BL/6 mice and BALB/c mice were purchased from
Jackson Laboratory (Bar Harbor, ME). OT-1/Rag-1 mice ex-
press an H-2Kb-restricted T cell receptor (TCR) specific for the
OVA-derived SIINFEKL peptide and were ordered from
Taconic Farms (Germantown, NY). All mice were main-
tained in a specific pathogen-free facility at the University of
North Carolina at Chapel Hill (Chapel Hill, NC), and the
University of North Carolina Institutional Animal Care and
Use Committee approved all procedures.
Antigen presentation assay in vitro after pAAV8/OVA
transfection or AAV8OVA vector transduction
Activation of CD8 + OT-1 T cells, measured by upregula-
tion of CD69 expression via flow cytometry, was used as a
readout for the efficiency of antigen presentation of the
SIINFEKL-containing capsids after transfection or transduc-
tion of AAVOVA plasmids and packaged vectors, respec-
tively. For transfection studies, 293 cells at 70–80%
confluency in a 6-well plate were transfected with 3 lg of
each plasmid including pXR8/OVA, pXX6-80, and pCBA-H-
2Kb, using polyethylenimine (PEI). After 24 hr, cells were
incubated with OT-1 T cells overnight. In transduction
studies, 2 · 105 HepG2/H-2Kb cells were incubated with
2 · 1011 particles of AAV vector for 24 hr, and then washed
and incubated with OT-1 T cells overnight.
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Flow cytometry
Phycoerythrin (PE)-labeled rabbit anti-mouse CD69 (clone
H1.2F3; BD Biosciences, San Jose, CA) and a fluorescein
isothiocyanate (FITC)-labeled anti-CD8 (clone 53-6.7; BD
Biosciences) were used to stain OT-1 T cells for 1 hr at 4C.
Cells were then washed and analyzed by flow cytometry
(UNC Chapel Hill Flow Cytometry Core Facility).
Luciferase imaging
BALB/c mice were retro-orbitally injected with 1 · 1011 par-
ticles of AAV/luc, and 1 week later, imaging was performed with
a Xenogen IVIS Lumina imaging system (Caliper Life Sciences/
PerkinElmer, Hopkinton, MA) after intraperitoneal injection of
d-luciferin substrate (120 mg/kg; NanoLight Technology, Pine-
top, AZ). Bioluminescence image analysis was carried out with
Living Image software (PerkinElmer, Waltham, MA).
ELISA for human AAT
The AAT concentration in blood was determined by
enzyme-linked immunosorbent assay (ELISA) as described
previously (C. Li et al., 2011).
In vivo CTL killing assay
As described previously (Li et al., 2009), 107 spleen cells
from C57BL mice were incubated with either a high dose
(5 M) or low dose (0.5 M) of carboxyfluorescein succinimidyl
ester (CFSE) in phosphate-buffered saline (PBS) at room
temperature for 12 min. Fetal bovine serum (FBS) was then
added to stop CFSE labeling. After washing, CFSEhigh cells
were incubated with OVA SIINFEKL (10 lg/ml). After
peptide pulsing, two populations (CFSEhigh and CFSElow) of
target cells were washed and mixed together, and then 107
cells of each population were injected into AAV8OVA-
immunized mice via the tail vein. Spleen cells were collected
24 hr later and analyzed by flow cytometry. The percent
specific lysis was determined by the following formulas: the
ratio of recovery of non-peptide-treated control spleen cells
to peptide-sensitized spleen cells = (percentage of CFSElow
cells)/(percentage of CFSEhigh cells). The percent specific
lysis (%) = 100 · [1 - (ratio of cells recovered from naive mice/
ratio of cells recovered from infected mice)].
In vivo T cell proliferation
C57BL/6 mice received AAVOVA vector via retro-orbital
administration. At various time points after AAV injection,
CFSE-labeled OT-1 T cells were transferred and T cell pro-
liferation was measured. OT-1 T cells were isolated from
spleen and incubated for 10 min at room temperature in PBS
with 5 lM CFSE at 2 · 107 cells/ml. The reaction was stopped
by the addition of FBS, cells were washed with PBS, and
5 · 106 CFSE-labeled OT-1 T cells were retro-orbitally injected
into C57BL/6 mice. On day 10 after OT-1 T cell transfer,
spleen cells were harvested and stained with antibodies
specific for TCR a-chain Va2 and CD8, or with PE-conjugated
H-2Kb/SIINFEKL tetramer. The frequency of proliferating T
cells was determined by the percentage of CFSE dilution
(Krishnan et al., 2007). The proliferation index (PI) was cal-
culated as the ratio of the total number of cells to the number
of cells initially residing in the parent generation.
Statistical analysis
The Student t test was used to carry out statistical analysis.
p < 0.05 was considered statistically significant.
Results
AAV8OVA capsid stimulates CD8 + OT-1
T cell reactivity
The AAV8 capsid protein is associated with increased
transduction efficiency and broader tissue tropism compared
with the AAV2 capsid, based on animal studies (Wu et al.,
2008). To study capsid-specific CTL reactivity, we previously
established a system in which the AAV2 virus was en-
gineered with an HI loop substitution in the AAV2 capsid,
using the chicken ovalbumin immunodominant SIINFEKL
peptide sequence (AAV2OVA) (Li et al., 2009). Using this
engineered AAV2OVA virus, we demonstrated that incu-
bation of AAV2OVA-transduced H-2Kb-expressing cells
with spleen cells from OT-1 mice induced the activation of
spleen cells in vitro, and administration of AAV2OVA virus
elicited a capsid-specific CTL immune response in mice (Li
et al., 2009, 2013). To investigate AAV8 capsid antigen pre-
sentation and immunogenicity, an AAV8OVA capsid, pre-
pared similarly to AAV2OVA, was engineered by replacing
the AAV8 HI loop with the OVA SIINFEKL peptide. First we
confirmed that the SIINFEKL epitope was processed and
presented, leading to OT-1 T cell stimulation. 293 cells were
cotransfected with AAV8OVA plasmid, an H-2Kb expression
plasmid, and pXX6-80, which encodes adenoviral proteins to
induce capsid expression. The stimulatory capacity of the 293
transfectants was then tested by coculture of the cells with
OT-1 T cells and by measuring upregulation of CD69 ex-
pression. 293 cells transfected with AAV8OVA plasmid ac-
tivated OT-1 T cells to a similar extent as AAV2OVA
transfectants, whereas cells transfected with a plasmid en-
coding wild-type AAV8 capsid or mock transfected did not
(Fig. 1). Next, we assessed the T cell-stimulatory capacity of
HepG2/H-2Kb cells, an H-2Kb-expressing hepatocyte cell
line (Li et al., 2013) that were transduced with AAV8OVA
packaged vector. Whereas wild-type AAV8 vector-
transduced HepG2/H-2Kb cells did not activate OT-1 T cells
relative to the no-vector control (0.20 and 0.12% CD8 +
CD69 + cells, respectively), AAV8OVA transduction resulted
in an increased percentage of CD8 + CD69 + T cells (1.29%).
However, this frequency was significantly lower than that
detected in cultures of AAV2OVA-transduced HepG2/H-
2Kb cells (10.89%; Fig. 1). These results indicate that the
SIINFEKL peptide in the context of the AAV8 capsid is
processed and presented, and stimulates CD8 + T cells albeit
at a reduced level compared with that resulting from the
AAV2OVA capsid.
Similar transduction efficiency and tropism in vivo
between AAV8OVA and wild-type AAV8 vectors
To study antigen presentation of the AAV8 capsid, we
initially determined whether insertion of the SIINFEKL epi-
tope into the HI loop of the AAV8 capsid altered tissue
tropism in vivo by monitoring luciferase expression in vivo in
mice injected with AAV8OVA/luc vector. As shown in
Fig. 2A, the pattern of luciferase expression was similar
for animals injected with AAV8OVA/luc and wild-type
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AAV8/luc. Notably, for both AAV8 vectors the strongest
signal was localized to the liver. Next, we injected AAV8O-
VA/AAT vector intravenously into mice, and measured
blood levels of AAT. Similar levels and kinetics of AAT ex-
pression over 3 months were detected in mice treated with
the AAV8/AAT and AAV8OVA/AAT vectors. Transgene
levels peaked within 2 weeks postinjection, remained stable
over 10 weeks, and decreased slightly at week 14 in both
groups (Fig. 2B).
T cell response to AAV8OVA capsid in mice
In previous studies, we demonstrated that muscular ad-
ministration of AAV2OVA vector mounts an OVA peptide-
FIG. 1. AAV8OVA capsid protein stimu-
lates OT-1 T cells in vitro. Activation of OT-1
T cells, based on upregulation of CD69 ex-
pression, was measured via flow cytometry
on coculture with (A) 293 H-2Kb cells trans-
fected with pAAV8OVA or pAAV2OVA
plasmids or left untreated (Control), and (B)
HepG2/H-2Kb cells transduced with pack-
aged AAV8OVA or AAV2OVA or left
untreated.
FIG. 2. AAV8OVA- and wild-type
AAV8-packaged vectors exhibit simi-
lar transduction profiles. (A) Particles
of AAV8OVA/luc or AAV8/luc vec-
tor (1 · 1011) were injected into BALB/
c mice and, 1 week later, luciferase
expression was monitored by whole
body imaging with a 10-sec exposure,
using a Xenogen IVIS Lumina system.
(B) C57BL/6 mice received intrave-
nously 1 · 1011 particles of AAV8O-
VA/AAT or AAV8/AAT vector, and
at various time points AAT levels in
blood were measured by ELISA.
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specific CTL response (Li, Hirsch et al., 2009). To determine
whether administration of the AAV8OVA vector elicited a
capsid CTL response in vivo, we administered AAV8OVA/
AAT vector at a dose of 1 · 1011 particles via muscular in-
jection into C57BL6 mice. Thirty days after AAV8OVA in-
jection, CFSE-labeled naive syngeneic mouse spleen cells
pulsed with OVA SIINFEKP peptide were infused into mice.
After 24 hr, the mice were killed and the amount of cells
pulsed with OVA peptide was calculated by flow cytometry.
As shown in Fig. 3, compared with control mice, no obvious
killing of OVA peptide-pulsed cells was observed in mice
receiving AAV8 or AAV8OVA vector.
Cross-presentation of AAV capsid antigen is dose
dependent in vivo
The efficiency of cross-presentation is weak compared
with endogenous antigen presentation. Usually high exoge-
nous antigen is required to elicit a strong cellular immune
response. In this study, we determined the efficiency of
in vivo SIINFEKL presentation by measuring the prolifera-
tion of transferred OT-1 T cells. To investigate the effects of
the dose of AAVOVA capsid on antigen presentation and
OT-1 T cell stimulation, various particle numbers of AA-
V2OVA vector were injected into C56BL/6 mice. When
compared with control mice without AAV2OVA treatment,
a dose of 5 · 1010 particles and higher induced OT-1 T-cell
proliferation (Fig. 4). However, no proliferation of OT-1 T
cells was detected in groups with doses of AAV2OVA less
than or equal to 1 · 1010 particles. Similar dose-dependent
antigen presentation was observed when using the AA-
V8OVA vector in vivo (data not shown). These data suggest
that efficient T cell stimulation occurs only with high doses of
AAV vector.
The extent and kinetics of AAV8 capsid antigen
presentation in vivo are similar to that of the AAV2 capsid
It has been shown that transgene expression gradually
increases after AAV2 administration in mice and peaks at
week 6, remaining stable long-term after vector injection.
Although the epitopes from the AAV2 capsid are cross-pre-
sented by antigen-presenting cells (APCs) to elicit a capsid-
specific CTL response, it is unclear whether the kinetics of
FIG. 3. No OVA-specific CTL-induced cy-
totoxic activity was elicited by muscular in-
jection of AAV8OVA vector. AAV8OVA/
AAT vector (1 · 1011 particles) was injected
into the muscle of C57BL/6 mice, and 4
weeks later the mice received via tail vein
injection a mixture of C57BL/6 mouse spleen
cells labeled with either a high concentration
of CFSE (CFSEH) and pulsed with SIINFEKL
peptide, or a low concentration of CFSE
(CFSEL). After 24 hr, single cells were iso-
lated from the spleens and analyzed by
flow cytometry to determine in vivo CTL-
mediated killing. (A) Each percentage rep-
resents the in vivo CTL-specific killing from
one of four mice. (B) Average killing effi-
ciency of OVA-specific CTLs elicited by
AAV8OVA muscle transduction in four
mice.
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antigen presentation of capsid epitopes in vivo after AAV
vector administration correspond with the dynamics of
transgene expression. To address this question, AAV2OVA/
AAT vector (2 · 1011 particles) was injected intravenously,
and at various time points splenic OT-1 T cells labeled with
CFSE were transferred into mice. Ten days posttransfer OT-1
T cell division was measured by flow cytometry. As shown
in Supplementary Fig. S2, over days 3–12 and days 21–30,
OT-1 T cell division was significantly increased in AAV2O-
VA/AAT vector-treated (86.73 and 55.63%, respectively)
versus control recipients (30 and 24.7%, respectively; p < 0.01
and p < 0.05, respectively). However, no difference was ob-
served for OT-1 cell proliferation between AAV2OVA and
control groups over days 41–50 and days 61–70 (p > 0.05).
This result indicates that antigen cross-presentation from the
AAV2 capsid occurs during the earlier time period after
AAV2 systemic administration.
To elucidate the kinetics of antigen presentation from
AAV8 transduction in vivo, we injected 1 · 1011 particles of
AAV8OVA/AAT or AAV2OVA vector into C57BL/6 mice,
and assessed proliferation of CFSE-labeled OT-1 T cells
transferred at various times after vector treatment. As shown
in Fig. 5, the frequency of proliferating OT-1 T cells was
significantly increased in mice injected with AAV8OVA be-
tween days 3–12 and days 21–30, relative to the control
group (p < 0.05). Although slightly more cells in division
from AAV8OVA application were observed compared with
that from control at later time points (days 41–50 and days
61–70), these findings were not statistically significant (Fig.
5B). Furthermore, no marked difference was observed in the
level and kinetics of OT-1 T cell proliferation between ani-
mals treated with AAV8OVA and AAV2OVA. These results
demonstrate that presentation of the SIINFEKL epitope is
similar for both AAV8 and AAV2 capsids.
Discussion
In this study we demonstrated through plasmid transfec-
tion and in vitro virus infection that integration of the OVA
immunodominant peptide SIINFEKL into the AAV8 capsid
induces antigen processing and presentation. Transgene ex-
pression pattern and kinetics subsequent to AAV8OVA
vector administration were similar to those of wild-type
AAV8 in vivo. A functional T cell response against OVA
peptide was not observed in vivo after AAV8OVA adminis-
tration. Antigen cross-presentation from AAV2 transduction
in vivo is dose dependent. Most significantly, similar to the
AAV2OVA vector, efficient antigen presentation on AA-
V8OVA vector transduction in vivo occurred within an early
time period.
It has been thought that AAV vectors induce a low cellular
immune response against the capsid because AAV vector
transduction does not produce any endogenous capsid
protein. However, clinical trials have suggested that capsid
antigen can be cross-presented on AAV transduction and
that AAV-transduced target cells can be eliminated by
FIG. 4. Capsid antigen presentation after AAVOVA transduction is dose responsive in vivo. Various doses of AAV2OVA/
AAT vector were injected intravenously into C57BL/6 mice and 3 days later, CFSE-labeled OT-1 T cells were transferred. On
day 10 after transfer OT-1 T cell proliferation in the spleen was assessed via flow cytometry. (A) Representative flow
cytometric histograms. (B) Average T cell proliferation and standard deviation of four mice. (C) Average proliferation index
(PI) and standard deviation. **p < 0.01, *p < 0.05 compared with control mice without AAV treatment.
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capsid-specific CTLs (Manno et al., 2006; Nathwani et al.,
2011). In one clinical trial, an AAV2 vector was used to de-
liver F9 into the liver via the arterial route. High F9 expres-
sion was observed at week 4 after AAV2 injection and
remained stable for 2 weeks before returning to the pre–gene
therapy baseline. It was suggested that memory CTLs
against the vector capsid were activated to clear AAV2-
transduced hepatocytes (Manno et al., 2006). Although
capsid-specific CTL clones were isolated from the patient,
and numerous experiments confirmed that capsid cross-
presentation can also be induced on AAV vector transduc-
tion in animal models, the results from this study and others
about the kinetics of AAV capsid cross-presentation, in
which efficient antigen presentation occurs in earlier periods
after AAV transduction, do not support the conclusion from
the clinical trial (H. Li et al., 2011). Alternative hypotheses
have been proposed, such as cryptic epitopes derived from
the F9 cDNA alternative reading frame (Li et al., 2009a),
which may provide an alternative rationale for the time
course of F9 decline observed in patients.
AAV8 is one of the most efficient liver-transducing sero-
types in animal models (Gao et al., 2006; Wu et al., 2008; C. Li
et al., 2011; Wang et al., 2012). AAV8 has been employed to
treat patients with severe hemophilia B in a phase 1 clinical
trial (Nathwani et al., 2011). Eight patients were enrolled for
treatment with self-complementary AAV8 vectors encoding
a codon-optimized human F9 transgene via peripheral vein
administration. At initial report, four of six patients have
discontinued F9 prophylaxis without spontaneous bleeding
after a follow-up of 6–16 months. One of two patients re-
ceiving a high dose of 2 · 1012 AAV8 particles per kilogram
had elevated liver transaminases with a drop in F9 level on
day 62 after gene transfer. Enzyme-linked immunospot
analysis detected a capsid-specific T cell response at 9 weeks,
suggesting that the decrease in F9 was related to capsid-
specific CTL reactivity (Nathwani et al., 2011). In this study we
have demonstrated that the efficiency of antigen cross-
presentation on AAV8 transduction in vivo was confined to
the earlier time points, similar to that with the AAV2 vector.
So, similarly, these results do not support the current inter-
pretation from AAV8/F9 clinical trials. To completely validate
in vivo mouse studies further experiments are needed to test
whether the kinetics with human hepatocytes is different from
that with mouse cells. In addition, alternative interpretations
of AAV liver transgene expression and CTL response corre-
lation remain open-ended and may require further clinical
studies specifically designed to answer these concerns.
Several studies have demonstrated that muscular injection
of AAV2 elicits a CTL response against capsid (Chen et al.,
2006; Li et al., 2007; Wang et al., 2007); however, the appli-
cation of AAV8 vector did not induce a capsid-specific CTL
response in mice (Wang et al., 2007). Consistent with this
observation, activation of capsid-specific T cells was not in-
duced after muscular injection of AAV8OVA vector in this
FIG. 5. The kinetics of capsid antigen presentation after AAV8OVA transduction in mice. Particles of AAVOVA/AAT virus
(1 · 1011) were injected intravenously into C57BL/6 mice, and at the indicated time points 5 · 106 CFSE-labeled OT-1 T cells
were transferred. Ten days after transfer proliferation of CD8 + OT-1 T cells was measured by flow cytometry. (A) Re-
presentative flow cytometric histograms. (B) Average T cell proliferation and standard deviation for four mice. (C) Average
proliferation index (PI) and standard deviation. **p < 0.01, *p < 0.05 compared with control mice without AAV treatment.
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study. One possibility is that AAV8 binding on the surface of
APCs is not mediated by heparan sulfate proteoglycan, the
primary receptor for AAV2 (Summerford and Samulski,
1998; Vandenberghe et al., 2006). It has been demonstrated
that heparan binding directs activation of T cells against
AAV 2 capsid (Vandenberghe et al., 2006). The lack of he-
paran binding by AAV8 may therefore account for the lack
of T cell activation by this vector.
Results from the aforementioned two clinical trials in pa-
tients with hemophilia B suggest that capsid-specific CTL
responses eliminate AAV-transduced cells at increasing
vector doses (Manno et al., 2006; Nathwani et al., 2011). The
data from our study are consistent with the finding that
higher doses of vector result in elevated antigen presentation
on the surface of target cells. To achieve optimal transgene
expression and decrease antigen load from input AAV vec-
tors, several approaches have been exploited: (1) generation
of double-stranded AAV vectors that can induce more rapid
and increased transgene expression compared with conven-
tional single-stranded cassettes (McCarty et al., 2001, 2003;
Wu et al., 2008); (2) modification of transgene cassette to
enhance transgene expression through optimization of the
promoter, poly(A), and/or transgene cDNA codon (Wu et al.,
2008); and (3) removal of empty particles in AAV prepara-
tions to decrease virus antigen load and increase transduc-
tion by decreasing competition for AAV binding and
intracellular trafficking with full virions (Urabe et al., 2006).
In conclusion, our study has demonstrated that AAV8
engineered with an OVA peptide can induce proliferation of
OVA-specific T cells through transfection of plasmid and
infection with virus, thus allowing for the monitoring of
in vivo capsid antigen presentation kinetics. There is a dose
dependency for AAV capsid antigen presentation in vivo.
Last, the kinetics of capsid antigen cross-presentation from
AAV8 is similar to that of AAV2 after in vivo administration—
antigen presentation for both serotypes occurs within an
early time-frame. Continued studies on the kinetics of capsid
antigen presentation from AAV transduction in vivo will help
in the design of effective approaches to prevent and block
capsid-specific CTLs against AAV-transduced target cells in
future clinical trials.
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